Promise of extended-release naltrexone is a red herring

The Lancet

Volumn 378, Issue 9792, 2011, Pages 663-

  Bart, Gavin ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; NARCOTIC ANTAGONIST; PLACEBO;

AGE; CLINICAL TRIAL (TOPIC); DRUG RELEASE; DRUG USE; EXTENDED DRUG RELEASE; HOSPITAL ADMISSION; HUMAN; LETTER; MORTALITY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; RELAPSE; URINALYSIS; DELAYED RELEASE FORMULATION; INJECTION; NOTE; RUSSIAN FEDERATION; DISEASE ASSOCIATION; DRUG OVERDOSE; DRUG RETENTION; PROBABILITY; RECURRENT DISEASE;

BUPRENORPHINE; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RUSSIA;

EID: 80051976323     PISSN: 0140-6736     EISSN: 1474-547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61328-7     Document Type: Letter

References (5)

1. E Krupitsky, EV Nunes, W Ling, A Illeperuma, DR Gastfriend, BL Silverman Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial Lancet 377 2011 1506 1513
2. K Miotto, MJ McCann, RA Rawson, D Frosch, W Ling Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts Drug Alcohol Depend 45 1997 131 134 (Pubitemid 27246414)
3. JC Ball, A Ross The effectiveness of methadone 1991 Springer-Verlag New York
4. J Kakko, KD Svanborg, MJ Kreek, M Heilig 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial Lancet 361 2003 662 668 (Pubitemid 36246548)
5. R Cornish, J Macleod, J Strang, P Vickerman, M Hickman Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database BMJ 341 2010 c5475